(HealthDay News) – For post-acute coronary syndrome patients, the risk of kidney injury is comparable for those treated with an intensive or moderate statin regime, according to a study presented during the American Heart Association’s Emerging Science Series Webinar, held on June 19.
Amy Sarma, MD, from Brigham and Women’s Hospital in Boston, and colleagues examined the incidence of kidney injury using data from two randomized trails (PROVE IT-TIMI 22, involving 4,162 patients, and Phase Z of the A-to-Z trial, involving 4,497 patients) that compared intensive vs. moderate statin therapy in patients after an acute coronary syndrome.
The researchers found that, across both trials, the incidence of kidney injury identified through creatinine elevation was similar between treatment arms. The incidence of kidney injury-related adverse events was similar for patients on intensive vs. less-potent statin therapy across both trials (0.92% vs. 0.91%; P=0.97).
“These findings provide important reassurance to clinicians that the use of some high-potency statins will not increase the risk of kidney injury,” Sarma said in a statement.
Several authors disclosed financial ties to the pharmaceutical industry.